GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » Equity-to-Asset

Race Oncology (ASX:RAC) Equity-to-Asset : 0.96 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Race Oncology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Race Oncology's Total Stockholders Equity for the quarter that ended in Dec. 2024 was A$20.72 Mil. Race Oncology's Total Assets for the quarter that ended in Dec. 2024 was A$21.67 Mil.

The historical rank and industry rank for Race Oncology's Equity-to-Asset or its related term are showing as below:

ASX:RAC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.91   Med: 0.96   Max: 0.99
Current: 0.96

During the past 9 years, the highest Equity to Asset Ratio of Race Oncology was 0.99. The lowest was 0.91. And the median was 0.96.

ASX:RAC's Equity-to-Asset is ranked better than
97.14% of 1505 companies
in the Biotechnology industry
Industry Median: 0.67 vs ASX:RAC: 0.96

Race Oncology Equity-to-Asset Historical Data

The historical data trend for Race Oncology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology Equity-to-Asset Chart

Race Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.96 0.96 0.96 0.96 0.91

Race Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.96 0.97 0.91 0.96

Competitive Comparison of Race Oncology's Equity-to-Asset

For the Biotechnology subindustry, Race Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Race Oncology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Race Oncology's Equity-to-Asset falls into.


;
;

Race Oncology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Race Oncology's Equity to Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Equity to Asset (A: Jun. 2024 )=Total Stockholders Equity/Total Assets
=18.312/20.229
=

Race Oncology's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=20.715/21.672
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Race Oncology  (ASX:RAC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Race Oncology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Race Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Race Oncology Business Description

Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.